DermTech Future Growth
Future criteria checks 1/6
DermTech is forecast to grow earnings and revenue by 13% and 16.7% per annum respectively while EPS is expected to grow by 36.2% per annum.
Key information
13.0%
Earnings growth rate
36.2%
EPS growth rate
Biotechs earnings growth | 20.6% |
Revenue growth rate | 16.7% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 06 Mar 2024 |
Recent future growth updates
Recent updates
We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate
Mar 02Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%
Mar 02Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price
Dec 28Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky
Sep 18Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?
Jun 14Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023
May 10DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%
May 06We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jan 16Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)
Nov 08Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?
Oct 11DermTech grants stock options
Oct 11Diving Into DermTech
Sep 01Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80
Aug 10DermTech: Approaching An All Or Nothing Moment
Jun 13We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jun 04DermTech - Taking A Second Look At The Growth Thesis
Mar 31DermTech: Adoption Headwinds And Earnings Misses
Dec 23Companies Like DermTech (NASDAQ:DMTK) Are In A Position To Invest In Growth
Dec 02DermTech - Game Changer, Set To Become The Leader In Skin Diagnostics
Sep 15We Think DermTech (NASDAQ:DMTK) Can Afford To Drive Business Growth
Sep 03DermTech: Transforming The Melanoma Diagnosis Landscape
Aug 31DermTech: Becoming More Appealing, Despite Nosebleed Valuation
Aug 09DermTech appoints former Myriad Genetics executive as new chief medical officer
Jun 16We're Not Very Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jun 05DermTech initiated buy at BTIG on the potential of PLA test
May 03DermTech rises 18% on report Cigna covering early melanoma detection test
Apr 27Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 25 | -78 | N/A | N/A | 1 |
12/31/2025 | 22 | -73 | N/A | N/A | 5 |
12/31/2024 | 17 | -77 | N/A | N/A | 5 |
12/31/2023 | 15 | -101 | -78 | -77 | N/A |
9/30/2023 | 14 | -110 | -88 | -86 | N/A |
6/30/2023 | 14 | -120 | -94 | -91 | N/A |
3/31/2023 | 14 | -118 | -96 | -92 | N/A |
12/31/2022 | 15 | -117 | -99 | -95 | N/A |
9/30/2022 | 15 | -115 | -99 | -97 | N/A |
6/30/2022 | 14 | -106 | -91 | -88 | N/A |
3/31/2022 | 13 | -93 | -80 | -76 | N/A |
12/31/2021 | 12 | -78 | -65 | -62 | N/A |
9/30/2021 | 11 | -63 | -48 | -46 | N/A |
6/30/2021 | 9 | -52 | -40 | -38 | N/A |
3/31/2021 | 7 | -45 | -34 | -32 | N/A |
12/31/2020 | 6 | -36 | -31 | -29 | N/A |
9/30/2020 | 5 | -31 | -30 | -28 | N/A |
6/30/2020 | 5 | -27 | -28 | -26 | N/A |
3/31/2020 | 4 | -21 | -23 | -22 | N/A |
12/31/2019 | 3 | -20 | -18 | -18 | N/A |
9/30/2019 | 2 | -18 | -13 | -13 | N/A |
6/30/2019 | 2 | -14 | -9 | -8 | N/A |
3/31/2019 | 3 | -13 | -8 | -8 | N/A |
12/31/2018 | 2 | -10 | -8 | -8 | N/A |
12/31/2017 | 2 | -8 | -6 | -6 | N/A |
6/30/2014 | 0 | -6 | N/A | -4 | N/A |
3/31/2014 | 0 | -6 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DMTK is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DMTK is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DMTK is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DMTK's revenue (16.7% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: DMTK's revenue (16.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DMTK's Return on Equity is forecast to be high in 3 years time